OA-01 Talquetamab (tal) + Daratumumab (dara) + Pomalidomide (pom) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 1b TRIMM-2 Study
Clinical Lymphoma Myeloma and Leukemia(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined